A Phase 4, Randomized, Double-blind, Placebo-controlled Study Of Continued Enzalutamide Treatment Beyond Progression In Patients With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer

Trial Profile

A Phase 4, Randomized, Double-blind, Placebo-controlled Study Of Continued Enzalutamide Treatment Beyond Progression In Patients With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Enzalutamide (Primary) ; Abiraterone acetate; Prednisone
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms PLATO
  • Sponsors Medivation; Pfizer
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 14 Dec 2016 Primary endpoint (Progression Free Survival (PFS)) has not been met, according to a Pfizer and Astellas Pharma joint media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top